April 19, 2022
THE ORTHOPAEDIC IMPLANT COMPANY ANNOUNCES FDA CLEARANCE, LAUNCH OF FIRST AND ONLY HIGH-VALUE DORSAL SPANNING PLATE
Latest Trauma Offering Expands the Utility of DRPx, the Company’s High-Value Wrist Fracture Plating System
RENO, Nev. (April 19, 2022) – The Orthopaedic Implant Company (OIC) today announced the FDA clearance and commercial launch of the market’s first and only high-value dorsal spanning plate. This addition to the company’s orthopaedic trauma implant portfolio expands the potential clinical impact of OIC’s DRPx wrist fracture plating system, fortifying it as the most comprehensive and value-driven alternative to other premium-priced plating systems currently in use.
Launched in August 2021, DRPx is the only high-value distal radius plating system available in the U.S., supporting a wide array of orthopaedic surgeons’ technique preferences while increasing opportunities for significant cost savings to help improve the financial viability of ambulatory surgery centers (ASCs), hospitals and their patients nationwide.
“Procedure volumes for the most common fractures are increasing quickly, so the ongoing challenge for our practice is finding more chances to improve value with those procedures and still uphold our high standards for patient outcomes,” said Dr. Peter Howard, M.D., Advanced Surgical Care of Clearwater, LLC, Clearwater, Florida. “The addition of OIC’s dorsal spanning plate to their DRPx system immediately allows us to address every indication our patients might face when it comes to wrist fracture care, all while continuing to drastically reduce our implant costs and maintain exceptional clinical outcomes.”
OIC’s wrist fracture plating system reduces implant costs, on average, by more than 50%1 and provides biomechanical and clinical outcome equivalency in comparison to branded and premium-priced implant systems.
“If we want value-based care to work then implant companies have to play their part,” said Itai Nemovicher, President and CEO, Orthopaedic Implant Company. “The reality right now is that ASCs are only being reimbursed at 53% the rate we’re seeing with hospitals performing the exact same procedures, so this is where we can make a huge difference for ASCs. Adding the dorsal spanning plate to our DRPx system provides surgeons and facilities with the chance to substantially increase value on a high-volume procedure, streamline operations and get the exact same clinical results they’re getting with more expensive implant systems.”
DRPx is commercially available in the United States. For more information, please visit www.orthoimplantcompany.com or email info@orthoimplantcompany.com.
References:
1McPhilamy, Austin, et al. “The Clinical and Economic Impact of Generic Locking Plate Utilization at a Level II Trauma Center.” Journal of Orthopaedic Trauma, Vol. 30, No. 12 Supplement, Dec 2016
About The Orthopaedic Implant Company
The Orthopaedic Implant Company (OIC) is changing the way orthopaedic implants are delivered and priced. OIC creates better value for the implants known and used every day. The company’s dynamic, human-focused strategy begins and ends with prioritizing people, not numbers. The team is comprised of industry experts who bring together decades of combined experience to create change in a healthcare system that must evolve.
Follow OIC on: Twitter,LinkedIn, and Facebook.
###
Media Contact:
Levitate
Adam King
(260)408-5383